Author's response to reviews

Title: Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure

Authors:

Andreanne Chabot (andreanne.chabot@usherbrooke.ca)
Bao Hua Jiang (jbaohua2009@gmail.com)
Yanfen Shi (yanfen.shi@icm-mhi.org)
Jean-Claude Tardif (jean-claude.tardif@icm-mhi.org)
Jocelyn Dupuis (jocelyn.dupuis@bellnet.ca)

Version: 2 Date: 2 November 2011

Author's response to reviews: see over
November 1, 2011

Dr. Jesper Kjaergaard
Associate Editor
*BMC Cardiovascular Disorders*
c/o Marinette Lacson
Journal Editorial Office
BioMed Central
U.K.

**RE:** Manuscript No. 9749544196081329

*Role of Aldosterone on Lung Structural Remodelling and Right Ventricular Function in Congestive Heart Failure*

Dear Dr. Kjaergaard,

Please find enclosed the revised version of the above-named manuscript together with a point-by-point reply to the comments from the referees. We have addressed all of the minor comments from the referees and hope that the manuscript will now be suitable for publication in *BMC Cardiovascular Disorders*. We sincerely thank your team and the reviewers for the interest in our work.

Kindly note the following modifications made within the Title Page:-

Page 1, line 7: deletion of Montreal,
Page 1, line 9: boul, reads boul.
Page 1, line 12: modification Québec to Quebec
Page 1, line 12: 1,2 reads 1
and, Page 2, line 10: reads … reduced left ventricular (LV) fractional …
Page 5, line 1: reads … (≥ 30% left ventricular (LV) wall …

Response to Reviewer 1.

We thank the Reviewer for his kind remarks on the timeliness and the significance of our work. The minor revision required by the reviewer has been done and we changed aldosterone for spironolactone on the first paragraph of page 12. Throughout the manuscript, we have removed Aldactone to use the generic term spironolactone as requested by the second referee.

.../2
Response to Reviewer 2.

We thank the Reviewer for his positive appraisal of our manuscript. There were no major revisions requested. The minor essential revisions have been addressed.

1. We have defined RVSP by RV systolic pressure; TAPSE by tricuspid annular plane systolic excursion; and, RV MPI by RV myocardial performance index, as requested.

2. We have considerably shortened the second paragraph and removed the text about the under-use of spironolactone and eplerenone from the Discussion, as required.

3. As suggested, we have removed the use of the trademark word Aldactone and replaced it by the generic term spironolactone.

4. We have deleted the plus signs that were present in the 7th paragraph of the Discussion. Thank you for noting this typo.

Discretionary Revisions.

1. We have removed the capitalized letter from the first letter of drug names.

2. After careful consideration, we have elected to maintain Table 1 and Table 2 as they were, as we grouped the LV parameters first and then the RV parameters second, and these are clearly identified. Furthermore, the RV and LV data are also clearly separated in the figures.

   Once again, we thank the reviewers for their comments that have improved the paper.

Sincerely,

Jocelyn Dupuis, MD, PhD

Email: jocelyn.dupuis@bellnet.ca

Encls./ap